Serina Therapeutics, Inc.
SER
$1.77
-$0.13-6.84%
AMEX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -5.94% | -6.85% | |||
| Gross Profit | 5.94% | 6.85% | |||
| SG&A Expenses | 9.80% | 2.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.18% | -2.89% | |||
| Operating Income | -1.18% | 2.89% | |||
| Income Before Tax | -107.69% | 27.79% | |||
| Income Tax Expenses | -61.11% | -- | |||
| Earnings from Continuing Operations | -106.77% | 27.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -100.00% | |||
| Net Income | -106.77% | 27.24% | |||
| EBIT | -1.18% | 2.89% | |||
| EBITDA | -1.28% | 3.03% | |||
| EPS Basic | -81.03% | 30.21% | |||
| Normalized Basic EPS | -40.72% | 29.73% | |||
| EPS Diluted | -82.73% | 29.96% | |||
| Normalized Diluted EPS | -40.72% | 29.73% | |||
| Average Basic Shares Outstanding | 12.97% | 3.14% | |||
| Average Diluted Shares Outstanding | 12.97% | 3.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||